M6-C artificial cervical disc effective treatment of degenerative cervical radiculopathy
Researchers have recently observed that treatment with M6-C demonstrated both safety and effectiveness for the treatment of degenerative cervical radiculopathy, as published in The Spine Journal.
a. Both ACDF and M6-C subjects reported significant improvements in patient-reported outcomes at all time points over baseline.
b. Overall SF-36 Physical Component Score and neck and arm pain scores were significantly improved for M6-C as compared to ACDF treatment.
c. CCS and mean Neck Disability Index improvements were similar between M6-C and ACDF.
d. Correspondingly, there were significantly fewer subjects that utilized pain medication or opioids following M6-C treatment at 24 months relative to baseline.
e. Range of motion was maintained in subjects treated with M6-C.
f. Subsequent surgical interventions, dysphagia rates, and serious adverse events were comparable between groups.
Hence, they concluded that "M6-C treatment demonstrated both safety and effectiveness for the treatment of degenerative cervical radiculopathy. Treatment with M6-C demonstrated noninferiority for the primary endpoint, indicating a similar ability to achieve CCS at 24 months. However, for the secondary endpoints, M6-C subjects demonstrated significantly improved pain and function compared to ACDF subjects, while maintaining range of motion, improving quality of life, and decreasing analgesic and opioid usage at 2 years postoperatively relative to baseline."